Particle.news

Download on the App Store

Global Survey of Eating Disorders Paves Way for Psilocybin and CBD Trials

Following a survey of more than 7,600 people with eating disorders, researchers will soon launch psilocybin trials in anorexia nervosa as cannabidiol studies near completion

Image
Image
Image

Overview

  • The survey gathered responses from over 7,600 individuals across 83 countries, making it the most comprehensive study of drug use in eating disorders to date.
  • Self-medication with cannabis and psychedelics earned the highest ratings for relieving core eating-disorder symptoms.
  • Commonly prescribed drugs such as antidepressants and stimulants were seen as largely ineffective for eating-disorder symptoms despite benefits for general mental health and specific subgroups.
  • Alcohol, nicotine and cocaine were reported to worsen both eating-disorder symptoms and overall mental health.
  • The University of Sydney’s Lambert Initiative and the Inside Out Institute are moving from observational findings to formal clinical evaluation with upcoming psilocybin trials for anorexia nervosa and a near-complete cannabidiol pilot study.